Jiangsu Hengrui Pharmaceuticals Co.,Ltd
1276.HK · Healthcare · Drug Manufacturers - Specialty & Generic · Valued as of 2026-11-03 · Statements 2025-12-31
How Each Value Is Built
The screener's three formulas on the reported figures. Each card reads the same way: the value as a sum of numbered terms, each term's calculation opened under it, from the reported figures to the value. The list ranks companies by their plain average over the market cap.
What it is worth
EPV + Growth
28.48B USD
what the normal year's earnings are worth for ever, plus growth that pays
Profit
23.09B USD
15 years of cash the shareholders can take out, and the equity left at year 15
FCFF
9.58B USD
15 years of cash for shareholders and lenders, less what is owed
Average Intrinsic Value
20.38B USD
The plain average of EPV, Profit and FCFF
Against the price
Market Cap
42.08B USD
the price on the date above times the shares
Intrinsic Value ÷ Market Cap
0.48×
the ratio the screener ranks by
Margin of Safety
-106.4%
1 − Market Cap / Average Intrinsic Value
Projections, not exact values. Intrinsic Values are projected from each company's past reports. They show which stocks look cheap compared with the others, not exactly what a stock is worth.
EPV of the Operations (NOPAT over WACC)
19.01B USD
Net cash today
+5.71B USD
Growth Value
+3.76B USD
Value
28.48B USD
①EPV (earnings power value)
19.01B USD②Net Cash Today
5.71B USD③Growth Value
3.76B USDMarket value
The price on the date above times the shares.
Value vs market
1 minus the market cap as a share of the value.
①Present Value of the 15 Years of FCFE
9.11B USD②Equity at Year 15, Today
13.98B USDMarket value
The price on the date above times the shares.
Value vs market
1 minus the market cap as a share of the value.
The projection was not made (a change in working capital above half the operating profit in the latest three years), so the value is the book value today, 9.58B USD, as the screener leaves it.
①Present Value of the 15 Years of FCFF
Not in the value②Invested Capital at Year 15, Today
Not in the value③Net Cash Today
Not in the valueMarket value
The price on the date above times the shares.
Value vs market
1 minus the market cap as a share of the value.
The Rates and the Capital the Values Read
The WACC and the cost of equity each value is discounted at, the book value and the net debt each starts from, and the seven quality metrics, from the same run.
The yearly return the shareholders require for the risk they carry; it is the rate that brings their future cash to today.
The tax the interest saves.
The interest the company paid: EBIT is the profit before tax plus the interest.
What the lenders are paid a year after the tax the interest saves.
The part of the capital the lenders put in, at market value.
Weighted average cost of capital: the yearly return the shareholders and the lenders together require, weighted by what each puts in; the rate that brings the firm's future cash to today.
Total Assets 10.43B USD − Total Liabilities 852.15M USD = Book Value Today 9.58B USD
Total Debt 10.02M USD − Cash and Short-Term Investments 5.72B USD = Net Debt Today -5.71B USD
The book value is what Profit starts from and what stands when a projection is not made; the book value plus the net debt is what FCFF starts from; the net debt comes off Greenwald's and FCFF's values before the shareholders.
Market Data
The provider's ratios and the analysts' consensus beside the argument; none of them enters a value.
Share price
49.71 HKD
Enterprise value
329.14B HKD
the provider's own figure
EV / EBITDA
34.78×
Price / book
4.53×
the provider's book
Price / earnings
37.06×
Return on equity
14.5%
the provider's figure, not this page's
Profit margin
24.9%
Revenue growth
13.0%
Analyst target, mean
79.00 HKD
Analysts
10
opinions in the consensus
Financial Statements
The annual lines the screener holds, year by year, in USD at each period's rate; the figures this valuation read are in its calculation above.